CSF3R and acute lymphoblastic leukemia: Though dasatinib has not been used in large clinical trials, including MDS/MPN diseases that are associated with CSF3R truncated mutations, it has shown a favorable outcome when used in a patient with B-cell acute lymphoblastic leukemia (ALL) associated with a CSF3R mutation.